Syntax Research, Inc. Lexicon Pharmaceuticals, Inc. Transaction History
Syntax Research, Inc.
- $139 Billion
- Q4 2024
A detailed history of Syntax Research, Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 142 shares of LXRX stock, worth $80. This represents 0.0% of its overall portfolio holdings.
Number of Shares
142
Previous 142
-0.0%
Holding current value
$80
Previous $223,000
52.91%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
132Shares Held
244MCall Options Held
52KPut Options Held
178K-
Artal Group S.A. Luxembourg, N4136MShares$77.6 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$22.2 Million1.27% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$5.64 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.88MShares$5.63 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.99MShares$5.12 Million0.02% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $108M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...